ArticleIndian dermatology online journal2026
Primary Localized Cutaneous Amyloidosis: A Histological and Immunohistochemical Appraisal.
Article in Indian dermatology online journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary localized cutaneous amyloidosis (PLCA) is a rare chronic heterogeneous group of disorders with deposition of abnormally folded beta-pleated protein in the dermo-epidermal junction and dermis. There are three major forms of PLCA, including lichen amyloidosis, macular amyloidosis, nodular amyloidosis, and a rare variant, amyloidosis cutis dyschromica. We aimed to evaluate the role of immunohistochemistry (IHC) in the diagnosis of PLCA. PATIENTS AND
methodsA retrospective 8-year audit (2017-2024) was performed. All cases of PLCA were subjected to a panel of IHC, including high molecular weight cytokeratin (HMWCK), Kappa and Lambda light chains; and serum amyloid A. The demographic details and clinical features, along with site predilection, were correlated with the pathological subtypes.
resultsWe included 42 cases of PLCA, among which lichen amyloidosis was the most common subtype (50%), followed by macular amyloidosis, nodular amyloidosis, and amyloidosis cutis dyschromica, with a predilection for the upper back. IHC displayed HMWCK positivity in cases of lichen amyloidosis (14/21, 66.7%), macular amyloidosis (7/11, 63.6%), and amyloidosis cutis dyschromica (2/3, 66.7%). All cases of nodular amyloidosis showed light chain restriction using a combination of IHC and direct immunofluorescence. LIMITATIONS: Retrospective nature of the study, relatively small sample size, and not performing IHC for other small molecular weight keratins.
conclusionThe findings in our study confirm that the amyloid in macular amyloidosis, lichen amyloidosis, and amyloidosis cutis dyschromica is derived from epidermal keratinocytes. IHC for HMWCK should be part of diagnostic workup as it can detect very small amount of amyloid deposition, which may be overlooked during routine evaluation. Nodular amyloidosis demonstrates light chain restriction, indicating the need to exclude systemic amyloidosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.